Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia

P. A. Cassileth, D. P. Harrington, J. D. Hines, M. M. Oken, J. J. Mazza, P. McGlave, J. M. Bennett, M. J. O'Connell

Research output: Contribution to journalArticle

115 Scopus citations

Abstract

The value of maintenance therapy after the achievement of complete remission in adult acute nonlymphocytic leukemia (ANLL) has never been clearly established. A randomized Eastern Cooperative Oncology Group (ECOG) study of postremission therapy compared outcomes in patients who received no further therapy to those administered long-term maintenance chemotherapy. Adverse results in the group administered no further therapy led to early termination of this trial after only 51 patients were randomized. Patients receiving no postremission therapy experienced significantly inferior remission durations (P = .002) compared with patients receiving maintenance therapy. All 26 patients in the group administered no postremission therapy have relapsed, with a median duration of remission of 4.1 months. In contrast, four of 25 patients (16%) who received maintenance therapy remain disease free, with a median duration of remission of 8.1 months.

Original languageEnglish (US)
Pages (from-to)583-587
Number of pages5
JournalJournal of Clinical Oncology
Volume6
Issue number4
DOIs
StatePublished - 1988

Fingerprint Dive into the research topics of 'Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia'. Together they form a unique fingerprint.

  • Cite this

    Cassileth, P. A., Harrington, D. P., Hines, J. D., Oken, M. M., Mazza, J. J., McGlave, P., Bennett, J. M., & O'Connell, M. J. (1988). Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. Journal of Clinical Oncology, 6(4), 583-587. https://doi.org/10.1200/JCO.1988.6.4.583